Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations among sleep quality, cognitive decline, and Alzheimer's disease pathology in older adults: A longitudinal study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Combining plasma biomarkers and cognitive challenge tests enhances prediction of functional trajectories of decline among older adults with cognitive impairment.

Journal of Alzheimer's disease : JAD·2026
Same author

Common Medical Comorbidities, Demographic Factors and Levels of Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration in Black/African American Older Adults.

Biomolecules·2026
Same author

Detecting Cognitive Impairment in African American Older Adults Using the LASSI-L and Plasma P-Tau<sub>217</sub>.

Advances in Alzheimer's disease·2026
Same author

Factors associated with discordant visual and quantitative amyloid PET results.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

David A Loewenstein1

  • 1University of Miami School of Medicine, Miami, FL, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

Plasma p-tau217 shows high accuracy for early Alzheimer's Disease (AD) detection in diverse populations. A specific cut-off effectively identifies AD pathology, potentially improving early diagnosis in underserved communities.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Gerontology

Background:

  • Plasma p-tau217 is a promising biomarker for early Alzheimer's Disease (AD) detection.
  • It shows diagnostic accuracy comparable to amyloid PET and CSF tests.
  • p-tau217 correlates with AD brain pathology and predicts cognitive decline.

Purpose of the Study:

  • To validate the diagnostic accuracy of plasma p-tau217 in a multicultural cohort.
  • To determine an optimal p-tau217 cut-off for AD detection.
  • To assess the utility of cognitive challenge tests in enhancing AD diagnosis.

Main Methods:

  • Evaluated 96 Hispanic/Latino and 56 Black/African American older adults.
  • Utilized MRI, amyloid PET scans, and plasma p-tau217 testing.
  • Performed logistic regression to differentiate cognitively unimpaired and mild cognitive impairment groups.

Main Results:

  • p-tau217 demonstrated strong discriminative ability (AUC=0.89) compared to amyloid PET.
  • A p-tau217 cut-off of 0.55 pg/ml achieved 85% sensitivity and 87% specificity.
  • Cognitive challenge tests showed high accuracy (80% sensitivity, 91.7% specificity) in differentiating diagnostic groups.

Conclusions:

  • The p-tau217 cut-off of 0.55 pg/ml effectively identifies AD pathology in a diverse population.
  • Plasma p-tau217 offers a sensitive and specific biomarker for early AD detection.
  • Cognitive challenge tests may augment diagnostic accuracy, aiding early detection in underserved populations.